A compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation and a preparation method thereof

By combining traditional Chinese medicine with paclitaxel broad-spectrum anticancer preparations, the toxic side effects and drug resistance of paclitaxel chemotherapy have been resolved, achieving significant anticancer effects and improved safety.

CN118217370BActive Publication Date: 2025-11-25JIANGSU SHANDONG BIOTECHNOLOGY GRP CO LTD
1 Cites 0 Cited by

Patent Information

Application Number
CN202410325270.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-21
Publication Date
2025-11-25
Estimated Expiration
2044-03-21

AI Technical Summary

Technical Problem

Existing paclitaxel chemotherapy drugs have significant side effects when treating cancer and are prone to drug resistance, which limits their clinical application.

Method used

This product is a compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation, composed of paclitaxel and other traditional Chinese medicine ingredients such as Scutellaria barbata, Agrimonia pilosa, and Scutellaria baicalensis. It is prepared into capsules, tablets, or pills through decoction, filtration, and vacuum concentration. It combines the theory of traditional Chinese medicine to regulate the body's physiological functions, reduce toxic side effects, and enhance anticancer effects.

Benefits of technology

It significantly inhibits cancer cell growth, reduces bone marrow suppression and immune function damage, improves drug safety, and enhances anti-cancer effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides a compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation is prepared from the following components in a mass fraction: 0.5-2.0 parts of paclitaxel powder with a purity of 99%, 18-30 parts of Herba Lysimachiae, 18-30 parts of Herba Impatientis, 18-30 parts of Radix Scrophulariae, 14-25 parts of Radix Curcumae, 14-25 parts of Radix Pini Strobil, 14-25 parts of Gynostemma pentaphyllum, 14-25 parts of Citrus medica, 10-18 parts of Radix Paeoniae Alba, 10-18 parts of Radix Paeoniae Rubra, 10-18 parts of Radix Rabdosiae, 6-12 parts of Fructus Schisandrae, 6-12 parts of Lumbricus, and 6-12 parts of Radix Glycyrrhizae. The compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation can not only significantly inhibit the growth of tumor cells on a lung cancer patient, but also significantly reduce bone marrow suppression and immune function damage caused by paclitaxel.
Need to check novelty before this filing date? Find Prior Art